# Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-for-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic-healthcare-data-sets/5a792e07-313c-4b6e-a098-39e274850db6

> FDA guidance document: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. Issue date: May 14, 2013. Get complete insights and analysis.

---

## Details

- Title: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2013-05-14
- Last Changed: 2025-01-31
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0057">FDA-2011-D-0057</a>

## Related Documents

- [Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacogenomics-premarket-evaluation-in-early-phase-clinical-studies-and-recommendations-for-labeling/74a84cb7-8271-4fc5-b011-1df725ecf2eb)
- [Immunogenicity Assessment for Therapeutic Protein Products](https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-assessment-for-therapeutic-protein-products/04e181cd-8e84-4961-b3ec-443e161c6965)
- [Q11 Development and Manufacture of Drug Substances](https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances/8d1aacb1-7da4-42f7-9a3a-18b2fc871411)